AstraZeneca's Enhertu breast cancer drug added to China's state insurance list
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...
GlobalData on MSN14 天
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
Daily5 天
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list
China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...
BioSpace2 小时
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...
FiercePharma13 天
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...